Registry For Patients Treated With BeneFix In Usual Care Setting In Germany
NCT ID: NCT00714415
Last Updated: 2018-10-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2008-01-31
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
NCT00581126
Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients
NCT00244114
Post Marketing Observational Study of Reformulated BeneFIX
NCT00835068
Study Evaluating rFIX; BeneFIX® in Hemophilia B
NCT00093171
Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use
NCT00167973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Patients with Hemophilia B
BeneFIX
Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BeneFIX
Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Inclusion in the ongoing prospective registry of European hemophilia B patients using BeneFIX®.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allgemeines Krankenhaus Linz, Kinderklinik
Linz, , Austria
Sonnengesundheitszentrum
München, Bavaria, Germany
Werlhof-Institut für Haemostaseologie GmbH
Hanover, Lower Saxony, Germany
Institut für Thrombophilie und Hämostaseologie
Münster, North Rhine-Westphalia, Germany
Vivantes Klinikum im Friedrichshain
Berlin, , Germany
Charite Campus Virchow-Klinikum, Padiatrie mit S. Hamatologie und Onkologie
Berlin, , Germany
Kinder- und Jugendarzt-Praxis Blaubeuren
Blaubeuren Abbey, , Germany
Institute of Experimental Haematology and Transfusion Medicine
Bonn, , Germany
Praxis fur Kinder- und Jugendmedizin, Homoopathie
Brannenburg, , Germany
Klinikum Bremen-Mitte gGmbH, Professor Hess Kinderklinik
Bremen, , Germany
Gemeinschaftspraxis fuer Haematologie und Onkologie
Cologne, , Germany
Klinikum Delmehorst gGmbH, Padiatrie
Delmenhorst, , Germany
CRC Coagulation Research Centre GmbH
Duisburg, , Germany
Universitaetsklinikum Duesseldorf, Klinik f. Kinder-Onkologie, Haematologie u. Klinische Immunologie
Düsseldorf, , Germany
Klinikum der Martin-Luther-Universitaet Halle-Wittenberg
Halle, , Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Universitaetsklinikum Eppendorf
Hamburg, , Germany
SRH Kurpfalzkrankenhaus Heidelberg
Heidelberg, , Germany
Klinikum Memmingen, Kinderklinik
Memmingen, , Germany
Universitaetskinderklinik und Poliklinik im Dr. von Haunerschen
München, , Germany
Universitaetsklinik fuer Kinder- und Jugendmedizin
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1821011
Identifier Type: OTHER
Identifier Source: secondary_id
3090A1-4406
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.